<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404908</url>
  </required_header>
  <id_info>
    <org_study_id>KE-0254/238/2017</org_study_id>
    <nct_id>NCT03404908</nct_id>
  </id_info>
  <brief_title>TAP vs QLB in Patients After Cesarean Delivery</brief_title>
  <official_title>Postoperative Analgesia With Transversus Abdominis Plane Block or Quadratus Lumborum Block in Patients After Cesarian Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of two types of analgesia after cesarean section All patients will be anesthetized
      with spinal technique. Ultrasound-guided transversus abdominis plane or quadratus lumborum
      block to treat postoperative pain. Postoperative pain will be measured with visual-analog
      scale (VAS). 1, 2, 6 months after surgery each patient will be called to assess neuropathic
      pain with Neuropathic Pain Symptom Inventory (NPSI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Written consent will be obtained before the cesarean section. Only subarachnoidally
      anesthetized patients may participate in the study. Pencil-point spinal needle and
      bupivacaine (Marcaine Heavy Spinal 0.5 %) will be used.

      At the end of surgery ultrasound-guided regional block will be performed. Each patient will
      be randomly allocated to one of the treated group: transversus abdominis plane block (TAP) or
      quadratus lumborum (QL). Patients receive 0.2 mL of local anesthetic solution (0.375 %
      ropivacaine) on each side.

      Postoperative pain will be measured with VAS (visual-analog scale) 2, 4, 8, 12 and 24 hours
      after the end of the operation.

      Paracetamol, metamizole, ketoprofen may be given as required. Whenever pain exceeds 40 (VAS)
      5 mg of morphine will be given intravenously (maximum two dosages per day).

      1, 3, 6 months patients will be called to assess neuropathic pain. Neuropathic Pain Symptom
      Inventory (NPSI) will be used.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 7, 2018</start_date>
  <completion_date type="Anticipated">April 17, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single (Participant)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>up to 24 hours after the surgery</time_frame>
    <description>Acute pain measured with VAS (visual-analogue scale). VAS in milimmeters. Minimum value 0, maximum 100. Less better - less severe pain. 0 no pain at all.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain</measure>
    <time_frame>6 months from the surgery</time_frame>
    <description>Neuropathic pain occurrence assessed with Neuropathic Pain Symptom Inventory (NPSI) 10 descriptive variables, each one from 0 to 10. 0 means no pain. 10 very high chance of occurrence of neuropathic pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cesarean Section</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-guided transversus abdominis plane block at the end of cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QLB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-guided quadratus lumborum block at the end of cesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP (transversus abdominis plane block)</intervention_name>
    <description>the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).</description>
    <arm_group_label>TAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QL (quadratus lumborum block)</intervention_name>
    <description>the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).</description>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>In both groups (TAP&amp;QLB) 0.375% ropivacaine will be given (0.2 mL/kg)</description>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle</intervention_name>
    <description>Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study</description>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day</description>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metamizole</intervention_name>
    <description>Intravenous metamizole will be used (1.0 gram), up to 4 grams per day</description>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen</intervention_name>
    <description>Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day</description>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)</description>
    <arm_group_label>TAP</arm_group_label>
    <arm_group_label>QLB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obtained consent

          -  singleton pregnancy

          -  subarachnoid anesthesia

        Exclusion Criteria:

          -  coagulopathy

          -  allergy to local anesthetics

          -  depression, antidepressant drugs treatment

          -  epilepsy

          -  usage of painkiller before surgery

          -  addiction to alcohol or recreational drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>parturients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirosław Czuczwar, M.D., PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Lublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michał Borys, M.D., PhD</last_name>
    <phone>+ 48 506350569</phone>
    <email>michalborys1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paweł Piwowarczyk, M.D., PhD</last_name>
    <phone>+48 511285352</phone>
    <email>piwowarczyk.pawel@gmail.com</email>
  </overall_contact_backup>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Michał Borys</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>transversus abdominis plane block</keyword>
  <keyword>quadratus lumborum block</keyword>
  <keyword>neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Dipyrone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

